| Identification | More | [Name]
Malotilate | [CAS]
59937-28-9 | [Synonyms]
MALOTILATE
MALOTILATUM
(1,3-dithiol-2-ylidene)-malonicacidiisopropylester
cl-1500
diisopropyl-1,3-dithiol-2-ylidenemalonate
diisopropyl1,3-dithiol-2-ylidenemalonate
nkk105
1,3-Dithiol-2-ylidenepropanedioic acid bis(1-methylethyl) ester
Dipropan-2-yl 2-(1,3-dithiol-2-ylidene)propanedioate
Hepation
Kantec
MaIotilate
1,3-Dithiol-2-ylidenemalonic acid diisopropyl ester
2-(1,3-Dithiol-2-ylidene)propanedioic acid diisopropyl ester
2-[1,3-Dithiol-2-ylidene]propanedioic acid di(isopropyl) ester
DDYM | [EINECS(EC#)]
261-987-3 | [Molecular Formula]
C12H16O4S2 | [MDL Number]
MFCD00867646 | [Molecular Weight]
288.38 | [MOL File]
59937-28-9.mol |
| Chemical Properties | Back Directory | [Melting point ]
60.5° | [Boiling point ]
400.61°C (rough estimate) | [density ]
1.3727 (rough estimate) | [refractive index ]
1.4950 (estimate) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
soluble in Methanol,Ether,Benzene | [form ]
powder to crystal | [color ]
White to Light yellow | [Merck ]
14,5712 | [InChI]
InChI=1S/C12H16O4S2/c1-7(2)15-10(13)9(11(14)16-8(3)4)12-17-5-6-18-12/h5-8H,1-4H3 | [InChIKey]
YPIQVCUJEKAZCP-UHFFFAOYSA-N | [SMILES]
C(OC(C)C)(=O)/C(=C1/SC=CS/1)/C(OC(C)C)=O | [CAS DataBase Reference]
59937-28-9(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Description]
Malotilate is a hepatoprotective agent reported to be effective in the treatment
of cirrhosis, chronic hepatitis and similar liver disorders. It appears to improve
hepatic function by increasing blood and bile flow and improving protein synthesis. | [Originator]
Nihon Nohyaku (Japan) | [Uses]
Malotilate is used as an adjunct treatment for hepatitis. It can activate liver function and inhibit the progression of liver fibrosis. It is suitable for the treatment of chronic hepatitis, compensated cirrhosis (to improve liver function), and cirrhosis with hypoalbuminemia caused by late-stage schistosomiasis. | [Definition]
ChEBI: Malotilate is an isopropyl ester. | [Brand name]
KANTEC | [in vitro]
the in-vitro invasion assay employing a rat lung endothelial cell monolayer indicated that pretreatment of the lung endothelial cells, but not c-sst-2 cells, with malotilate reduced the invasion of the rle monolayer by c-sst-2 cells significantly. the in-vitro vascular permeability assay also demonstrated malotilate could prevent the permeability increase of the lung endothelial cell monolayer by serum starvation. in contrast, the gelatinase production and adhesion to the rle cell monolayer of c-sst-2 cells were not affected by malotilate treatment [1]. | [in vivo]
malotilate was administered to syngeneic shr rats orally from 7 days before or after s.c. inoculation of c-sst-2 cells until the end of the experiments. in the malotilate-treated rats, pulmonary metastasis was suppressed markedly when compared with the non-treated rats. moreover, in the rats treated with malotilate for 19 days after inoculation of c-sst-2 cells, lung metastasis was also suppressed significantly [1]. | [References]
[1] nagayasu h,hamada j,kawano t,konaka s,nakata d,shibata t,arisue m,hosokawa m,takeichi n,moriuchi t. inhibitory effects of malotilate on invasion and metastasis of rat mammary carcinoma cells by modifying the functions of vascular endothelial cells. br j cancer.1998 may;77(9):1371-7.
[2] takase s,matsuda y,yasuhara m,takada a. effects of malotilate treatment on alcoholic liver disease. alcohol.1989 may-jun;6(3):219-22. |
|
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
|